Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity
- 17 May 2012
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 39 (8), 643-649
- https://doi.org/10.1111/j.1440-1681.2012.05724.x
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Role of microRNAs in diabetes and its cardiovascular complicationsCardiovascular Research, 2011
- Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial functionBiochemical Pharmacology, 2011
- Angiotensin-(1–7) prevents diabetes-induced attenuation in PPAR-γ and catalase activitiesEuropean Journal of Pharmacology, 2010
- Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.)Sm., in STZ-induced diabetic ratsChemico-Biological Interactions, 2009
- Haem oxygenase‐1 induction protects against tumour necrosis factor α impairment of endothelial‐dependent relaxation in rat isolated pulmonary arteryBritish Journal of Pharmacology, 2009
- Impaired Coronary Microvascular Dilation Correlates with Enhanced Vascular Smooth Muscle MLC Phosphorylation in Diabetes1Microcirculation, 2009
- Vascular effects of PPARγ activators – From bench to bedsideProgress in Lipid Research, 2007
- General administration of cyclohexenonic long-chain fatty alcohol ameliorates hyperreactivity of STZ-induced diabetic rat aortaLife Sciences, 2006
- Peroxisome Proliferator-Activated Receptors and AtherogenesisCirculation Research, 2004
- Expression of Peroxisome Proliferator-Activated Receptor α (PPARα) in Primary Cultures of Human Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1998